Investor Presentaiton slide image

Investor Presentaiton

Financial Forecasts for FY2023 Financial Forecasts for FY2023 (Core Basis) Billions of yen Revenue FY2022 Results 555.5 FY2023 Forecasts Value Change FX % Cost of sales Gross profit SG&A expenses 176.7 378.8 305.6 R&D expenses 106.1 84.0 Other operating income and expenses 49.2 12.0 (Core basis) Core operating profit 16.4 (62.0) 362.0 (193.5) (9.5) (34.8) 132.0 (44.7) (3.0) (25.3) 230.0 (148.8) (6.5) (39.3) 220.0 (85.6) (6.7) (28.0) (22.1) (2.3) (20.8) (37.2) (0.2) (75.6) (78.4) 2.3 Expect both revenue and profit down for FY2023 Revenue: Japan (¥21.1B), North America (¥119.7B), China (¥6.4B), Other Business (¥43.3B) ⚫ Japan will be affected by termination of sales collaboration of Trulicity, NHI price revision • North America will be affected by loss of exclusivity of LATUDAⓇ, while ORGOVYX®, MYFEMBREE®, GEMTESAⓇ will grow ⚫ China will decrease due to the growing impact of Volume- Based Procurement application for MEROPENⓇ ⚫ Other Business will decrease due to the transfer of subsidiaries Non-recurring item (93.3) (16.0) 77.3 (negative number indicates loss) SG&A and R&D expenses: Operating profit (77.0) (78.0) (1.0) 1.3 •SG&A and R&D will decrease mainly due to the Income tax expenses 48.8 (1.0) (49.8) (96.7) (80.0) 16.7 (74.5) (80.0) (5.5) the parent Net profit Net profit attributable to owners of ROE (%) ROIC (%) Sumitomo Pharma (14.7%) (21.9%) (3.9%) (8.5%) FX rates: FY2022 Results 1US$ = ¥135.51, 1RMB = \19.75 FY2023 Forecasts: 1US$ = ¥130.00, 1RMB = \19.50 Combination of Group Companies in the U.S. Other operating income and expenses (Core basis): ⚫ Sale of assets will decrease Non-recurring item: • Temporary expenses associated with the Combination of Group Companies in the U.S. are expected © Sumitomo Pharma Co., Ltd. All Rights Reserved. 11 7.4
View entire presentation